PT  - JOURNAL ARTICLE
AU  - Sinclair, Heather Q.
ED  - Bach, Richard D.
TI  - Rosiglitazone and New Insights in the BARI 2D Trial
DP  - 2010 Sep 01
TA  - MD Conference Express
PG  - 24--25
VI  - 10
IP  - 6
4099  - http://mdc.sagepub.com/content/10/6/24.short
4100  - http://mdc.sagepub.com/content/10/6/24.full
AB  - According to post hoc analyses of the Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes [BARI 2D; NCT00006305] data, rosiglitazone is not associated with an increased risk of major adverse cardiovascular events, including myocardial infarction and death, in patients with type 2 diabetes mellitus and established coronary artery disease.